

Extraordinary Report

March 24 , 2017

(TRANSLATION)

Note for readers of this English translation

On March 24, 2017, Chugai Pharmaceutical Co., LTD. (the “Company”) filed its Japanese-language Extraordinary Report (Rinji Houkokusho) (the “Report”) with the Director-General of the Kanto Financial Bureau in Japan in connection with the Company's shareholders' voting results for proposals acted upon at the 105th Annual General Meeting of Shareholders held on March 23, 2017 pursuant to the Financial Instruments and Exchange Act of Japan. This document is an English translation of the Report in its entirety.

1. Reason for submitting the Extraordinary Report

Given that resolutions were made for the proposals at the 106th Annual General Meeting of Shareholders (the “Meeting”) held on March 23, 2017, Chugai Pharmaceutical Co., Ltd (the “Company”) submits this Extraordinary Report under the provisions of Article 24-5, Paragraph 4, of the Financial Instruments and Exchange Act of Japan and Article 19, Paragraph 2, Item 9-2, of the Cabinet Office Ordinance on Disclosure of Corporate Information, etc.

2. Matters reported

(1) Date when the Meeting was held: March 23, 2017

(2) Matters for resolution

Proposal 1 Appropriation of Surplus

Concerning the year-end dividend

JPY 26 per share of common stock of the Company

Proposal 2 Election of Four (4) Directors

Masayuki Oku, Yoichiro Ichimaru, Christoph Franz, Daniel O'day were elected as directors of the Company.

Proposal 3 Election of One (1) Audit & Supervisory Board Member

Mamoru Togashi was elected as Audit & Supervisory Board Member of the Company.

Proposal 4 Determination of the Amount and Contents of Remuneration for

Granting Restricted Stock to Directors

- (3) Number of voting rights concerning the indication of "for", "against" or "abstain" for each proposal; Requirements for approving the proposals; Results of resolutions

Proposal	For	Against	Abstention	Ratio of favorable votes	Results
Proposal 1	5,011,748	251	1,449	99.27%	Approved
Proposal 2					
Masayuki Oku	4,871,648	137,935	3,861	96.49%	Approved
Yoichiro Ichimaru	5,010,509	1,036	1,902	99.24%	Approved
Christoph Franz	4,975,245	34,560	3,642	98.54%	Approved
Daniel O'day	4,963,389	46,416	3,642	98.31%	Approved
Proposal 3					
Mamoru Togashi	4,868,100	143,894	1,450	96.42%	Approved
Proposal 4	4,984,907	28,040	501	98.74%	Approved

Notes: Requirements for the approval of each proposal are as follows.

- 1) The resolution for Proposal 1 and Proposal 4 must be adopted by a majority of the votes of the shareholders present who are entitled to exercise voting rights.
 - 2) The resolution for Proposals 2 and Proposal 3 must be adopted by a majority of the votes of the shareholders present at the meeting where the shareholders holding one-third (1/3) or more of the voting rights of the shareholders entitled to exercise their voting rights are present.
- (4) Reason why a portion of the voting rights held by the shareholders present at the Meeting held on March 23, 2017 was not added to the number of voting rights

Because the required majority approval for each proposal was met by the votes exercised prior to the Meeting held on March 23, 2017 and the votes exercised by a portion of shareholders present at the Meeting held on March 23, 2017 in terms of Japanese Companies Act and confirmed by the Company, the number of voting rights concerning the indication of "for" "against" or "abstain" as to each proposal of the shareholders present at the Meeting held on March 23, 2017 not confirmed by

the Company are not tallied.